Hsbc Holdings PLC Takes Position in Keros Therapeutics, Inc. $KROS

Hsbc Holdings PLC bought a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 53,986 shares of the company’s stock, valued at approximately $599,000. Hsbc Holdings PLC owned 0.27% of Keros Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. The Manufacturers Life Insurance Company grew its stake in shares of Keros Therapeutics by 8.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after buying an additional 988 shares during the period. UBS Group AG raised its stake in Keros Therapeutics by 1.1% during the 3rd quarter. UBS Group AG now owns 103,864 shares of the company’s stock worth $1,643,000 after buying an additional 1,091 shares during the period. Strs Ohio raised its stake in Keros Therapeutics by 3.9% during the 4th quarter. Strs Ohio now owns 29,300 shares of the company’s stock worth $597,000 after buying an additional 1,100 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares in the last quarter. Finally, Financial Management Professionals Inc. bought a new position in Keros Therapeutics in the fourth quarter worth approximately $29,000. 71.56% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total transaction of $28,140.00. Following the transaction, the director directly owned 9,767 shares of the company’s stock, valued at $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director owned 9,767 shares in the company, valued at approximately $104,799.91. This trade represents a 21.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,425 shares of company stock valued at $89,994 in the last three months. 12.60% of the stock is currently owned by insiders.

Keros Therapeutics Stock Up 2.5%

KROS stock opened at $10.22 on Friday. Keros Therapeutics, Inc. has a twelve month low of $9.69 and a twelve month high of $22.55. The stock’s 50 day moving average is $10.73 and its 200-day moving average is $12.72. The firm has a market capitalization of $202.27 million, a PE ratio of -3.40 and a beta of 0.97.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The company had revenue of $0.37 million for the quarter, compared to the consensus estimate of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. On average, equities research analysts anticipate that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.40.

Keros Therapeutics Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.